Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma
The acquisition of a multi-drug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the Cereblon (CRBN) protein include widely-used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase modulator drugs (CELMoDs), in clinical trials. CRBN genetic disruption causes...
Κύριοι συγγραφείς: | Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
American Society of Hematology
2022
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients
ανά: Gooding, S, κ.ά.
Έκδοση: (2021) -
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
ανά: Kubra Karagoz, κ.ά.
Έκδοση: (2022-02-01) -
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
ανά: Kazuhito Suzuki, κ.ά.
Έκδοση: (2023-11-01) -
Conservation of the COP9/signalosome in budding yeast
ανά: Susan Wee, κ.ά.
Έκδοση: (2002-08-01) -
Conservation of the COP9/signalosome in budding yeast
ανά: Dubiel Wolfgang, κ.ά.
Έκδοση: (2002-08-01)